LNC Pharma Pte. Ltd. (hereinafter referred to as “LNC Pharma”), a wholly-owned subsidiary of Yantai Lannacheng Biotechnology Co., Ltd. (hereinafter referred to as LNC), manages international affairs. LNC was co-founded in 2021 by Yantai Dongcheng Pharmaceutical Group Co., Ltd., a leading nuclear medicine enterprise in China, and Professor Xiaoyuan (Shawn) Chen, a renowned expert in molecular imaging and nanomedicine. LNC is committed to global R&D and the regulatory registration of radiotheranostics.  More information about our pipeline and ongoing clinical trials is available on our website: https://en.dc-lnc.com/pro1. 

LNC PHARMA PTE. LTD. is delighted to announce that our significant novel radiopharmaceutical, 177Lu-LNC1004 Injection, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) recently. This designation highlights the potential of 177Lu-LNC1004 as a targeted treatment for patients with metastatic, radioiodine-refractory differentiated thyroid cancer who progress on or do not tolerate tyrosine kinase inhibitor therapy.

On April 24, the 3rd meeting of the 6th Board of Directors of DC PHARMA approved the " Proposal on Introducing Investors to the holding subsidiary for Capital Increase and Share Expansion ". It was agreed that Yantai Lannacheng Biotechnology Co., Ltd., as the holding subsidiary of DC PHARMA, would introduce investors in the way of capital increase and share expansion. Shenzhen Capital Group Co.,Ltd led the investment, and followed by Qianyanfangzhou, Yantai Caijing, Longxin Tongzi, Aohua Qingjie Nengyuan. This B+ financing successfully raised a total of RMB 300 million with a pre-investment valuation of RMB 1.95 billion.

Recently, LNC PHARMA received the ⁶⁸Ga-LNC1007 FDA (Food and Drug Administration) IND approval, and will conduct Phase I clinical trial in the near future.

Recently, LNC received the 177Lu-LNC1004 Injection IND approval from the NMPA (National Medical Products Administration), and will conduct the Phase I clinical trial in the near future.

Recently, LNC received the EC (Ethics Committee) approval from the Beijing Hospital regarding the 18F-LNC1001 Injection and will conduct the Phase III clinical trial in the near future.

Recently, LNC received the 177Lu-LNC1003 Injection IND approval from the NMPA (National Medical Products Administration), and will conduct the Phase I clinical trial in the near future.

Recently, LNC PHARMA received the IND approval for the 177Lu-LNC1003 Injection from the HSA (Health Sciences Authority), and will conduct the Phase I clinical trial in the near future.

Before then, 177Lu-LNC1003 injection has also obtained the IND approval from the US FDA (Food and Drug Administration) on Apr. 2023.